InterVenn Biosciences Partners with Aranscia
Innovative Collaboration Aims to Transform Cancer Diagnostics
In a transformative move for the diagnostics landscape, InterVenn Biosciences has joined forces with Aranscia, a leader in clinical technology solutions. Together, they strive to enhance the availability of the GlycoKnow™ Ovarian cancer diagnostic test, crucial for early detection and effective treatment.
Strategic Goals of the Partnership
This strategic partnership marks a significant advancement in utilizing Aranscia's comprehensive suite of laboratory and technology solutions, which will support the commercialization of InterVenn's groundbreaking test. The collaboration leverages both companies' strengths to improve clinical workflows and broaden accessibility for healthcare practitioners.
Aranscia’s Role
Under the terms of this multi-year collaboration, Aranscia will provide its software solutions, such as Spesana and 2bPrecise, which are designed to integrate seamlessly with existing electronic medical records. This integration is pivotal for streamlining diagnostic processes related to women’s health and oncology.
Comments from Leadership
Andrew Quong, CEO of InterVenn, expressed enthusiasm regarding this collaboration. "We're thrilled to partner with Aranscia, aiming to enhance care and treatment journeys for individuals through insights provided by the GlycoKnow Ovarian test and future innovations," he stated. Quong highlighted Aranscia's proven track record in personalized diagnostic initiatives as a key factor in the partnership.
The Impact of GlycoKnow™
The GlycoKnow Ovarian test is a game-changing blood-based liquid biopsy aimed at differentiating between benign pelvic masses and ovarian cancer. By establishing accuracy in diagnostics, it aids clinicians in delivering timely and appropriate care while minimizing unnecessary procedures.
Clinical Relevance
This innovative test not only contributes to effective cancer diagnostics but also aligns with broader efforts to facilitate patient-centric care. By addressing benign and malignant conditions with a non-invasive approach, the GlycoKnow Ovarian test signifies an important shift toward personalized medicine.
Shared Vision for the Future
The partnership is more than just operational; it's a shared mission. Bryon Cipriani, CEO of Aranscia, emphasized their commitment to assisting InterVenn in improving ovarian cancer detection and care. He noted that their combined expertise in diagnostics will enhance the speed and accuracy of results, benefiting patients significantly.
In summary, this collaboration represents a significant leap toward enhancing cancer diagnostic capabilities. By combining forces, InterVenn and Aranscia aim to lead the way in innovative healthcare, ultimately benefiting countless individuals battling ovarian cancer.
About InterVenn Biosciences
InterVenn Biosciences decodes glycoproteomic information to enrich predictive, preventative, and personalized healthcare. With its cutting-edge platform, GlycoVision™, the company seeks to uncover vital insights into health through advanced technology. They collaborate with healthcare professionals and researchers to streamline disease detection and treatment strategies.
About Aranscia
Aranscia is dedicated to improving healthcare outcomes through advanced diagnostic software and innovative technologies. Its offerings in molecular diagnostics, genomics, and clinical workflow solutions establish it as a pivotal partner in the realm of precision medicine.
Frequently Asked Questions
What is the purpose of the GlycoKnow Ovarian test?
The GlycoKnow Ovarian test is designed to distinguish between benign pelvic masses and ovarian cancer through a non-invasive blood analysis.
Who are the partners involved in this collaboration?
The two partners are InterVenn Biosciences, specializing in liquid biopsy diagnostics, and Aranscia, known for its clinical technology solutions.
How does Aranscia support InterVenn?
Aranscia provides essential software solutions and logistical support to streamline clinical workflows and enhance patient care delivery.
Why is early detection critical in ovarian cancer?
Early detection of ovarian cancer is crucial as it significantly improves the chances of successful treatment and outcomes for patients.
What other services does Aranscia offer?
Aranscia offers a wide range of diagnostic software, clinical workflow solutions, and services in fields such as precision oncology, pharmacogenomics, and infectious disease management.
